Taylan E, Oktay KH. Current state and controversies in fertility preservation in women with breast cancer. World J Clin Oncol 2017; 8(3): 241-248 [PMID: 28638793 DOI: 10.5306/wjco.v8.i3.241]
Corresponding Author of This Article
Kutluk H Oktay, MD, PhD, Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, United States. koktay@fertilitypreservation.org
Research Domain of This Article
Oncology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jun 10, 2017; 8(3): 241-248 Published online Jun 10, 2017. doi: 10.5306/wjco.v8.i3.241
Current state and controversies in fertility preservation in women with breast cancer
Enes Taylan, Kutluk H Oktay
Enes Taylan, Kutluk H Oktay, Innovation Institute for Fertility Preservation and In Vitro Fertilization, New York, NY 10019, United States
Enes Taylan, Kutluk H Oktay, Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, Valhalla, NY 10595, United States
Author contributions: Both authors contributed to this paper with conception, literature review and analysis, drafting, revision, editing, and approval of the final version.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Kutluk H Oktay, MD, PhD, Laboratory of Molecular Reproduction and Fertility Preservation, Department of Obstetrics and Gynecology, New York Medical College, 40 Sunshine Cottage Rd, Valhalla, NY 10595, United States. koktay@fertilitypreservation.org
Telephone: +1-877-4923666
Received: February 17, 2017 Peer-review started: February 17, 2017 First decision: April 14, 2017 Revised: May 4, 2017 Accepted: May 12, 2017 Article in press: May 15, 2017 Published online: June 10, 2017
Abstract
On average, over 25000 women are diagnosed with breast cancer under the age of 45 annually in the United States. Because an increasing number of young women delay childbearing to later life for various reasons, a growing population of women experience breast cancer before completing childbearing. In this context, preservation of fertility potential of breast cancer survivors has become an essential concept in modern cancer care. In this review, we will outline the currently available fertility preservation options for women with breast cancer of reproductive age, discuss the controversy behind hormonal suppression for gonadal protection against chemotherapy and highlight the importance of timely referral by cancer care providers.
Core tip: Field of fertility preservation has experienced remarkable advances within the last 20 years. As a result, young cancer survivors have numerous options to maintain an important aspect of their quality of life, fertility. In this article we review the current state and controversies in fertility preservation. The article should be an important resource for professionals who take care of young women with breast cancer and other malignancies.
